nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—PSIP1—prostate gland—prostate cancer	0.0114	0.0844	CbGeAlD
L-DOPA—PSIP1—seminal vesicle—prostate cancer	0.00965	0.0714	CbGeAlD
L-DOPA—CYP2D6—Bicalutamide—prostate cancer	0.00796	0.504	CbGbCtD
L-DOPA—PSIP1—renal system—prostate cancer	0.00778	0.0575	CbGeAlD
L-DOPA—PSIP1—urethra—prostate cancer	0.00764	0.0565	CbGeAlD
L-DOPA—SLC7A8—prostate gland—prostate cancer	0.00752	0.0556	CbGeAlD
L-DOPA—CYP2D6—Abiraterone—prostate cancer	0.0066	0.418	CbGbCtD
L-DOPA—PSIP1—bone marrow—prostate cancer	0.00588	0.0435	CbGeAlD
L-DOPA—SLC7A5—prostate gland—prostate cancer	0.00583	0.0431	CbGeAlD
L-DOPA—SLC7A8—renal system—prostate cancer	0.00513	0.0379	CbGeAlD
L-DOPA—PSIP1—testis—prostate cancer	0.00503	0.0372	CbGeAlD
L-DOPA—SLC7A5—seminal vesicle—prostate cancer	0.00493	0.0365	CbGeAlD
L-DOPA—CYP2D6—urine—prostate cancer	0.00473	0.035	CbGeAlD
L-DOPA—SLC16A10—prostate gland—prostate cancer	0.00446	0.033	CbGeAlD
L-DOPA—DDC—renal system—prostate cancer	0.00444	0.0328	CbGeAlD
L-DOPA—SLC7A5—epithelium—prostate cancer	0.00428	0.0317	CbGeAlD
L-DOPA—DRD4—testis—prostate cancer	0.00419	0.031	CbGeAlD
L-DOPA—SLC7A5—urethra—prostate cancer	0.0039	0.0289	CbGeAlD
L-DOPA—PSIP1—Teniposide—Etoposide—prostate cancer	0.00387	0.406	CbGdCrCtD
L-DOPA—PSIP1—Podofilox—Etoposide—prostate cancer	0.00387	0.406	CbGdCrCtD
L-DOPA—PSIP1—lymph node—prostate cancer	0.00364	0.027	CbGeAlD
L-DOPA—SLC15A1—epithelium—prostate cancer	0.00356	0.0263	CbGeAlD
L-DOPA—SLC7A8—testis—prostate cancer	0.00331	0.0245	CbGeAlD
L-DOPA—SLC15A1—renal system—prostate cancer	0.0033	0.0244	CbGeAlD
L-DOPA—SLC16A10—epithelium—prostate cancer	0.00328	0.0243	CbGeAlD
L-DOPA—SLC7A5—bone marrow—prostate cancer	0.003	0.0222	CbGeAlD
L-DOPA—DDC—testis—prostate cancer	0.00287	0.0212	CbGeAlD
L-DOPA—SLC7A5—testis—prostate cancer	0.00257	0.019	CbGeAlD
L-DOPA—SLC7A8—lymph node—prostate cancer	0.0024	0.0178	CbGeAlD
L-DOPA—DDC—lymph node—prostate cancer	0.00208	0.0154	CbGeAlD
L-DOPA—Masoprocol—IGF1R—prostate cancer	0.00199	0.141	CrCbGaD
L-DOPA—SLC16A10—testis—prostate cancer	0.00197	0.0145	CbGeAlD
L-DOPA—Melphalan—SLC22A3—prostate cancer	0.00195	0.138	CrCbGaD
L-DOPA—SLC7A5—lymph node—prostate cancer	0.00186	0.0138	CbGeAlD
L-DOPA—SLC16A10—lymph node—prostate cancer	0.00143	0.0105	CbGeAlD
L-DOPA—PSIP1—Levonorgestrel—Ethinyl Estradiol—prostate cancer	0.00138	0.144	CbGdCrCtD
L-DOPA—L-Tyrosine—TH—prostate cancer	0.00131	0.0927	CrCbGaD
L-DOPA—DRD2—testis—prostate cancer	0.00124	0.00921	CbGeAlD
L-DOPA—CYP2D6—Doxorubicin—prostate cancer	0.00122	0.0773	CbGbCtD
L-DOPA—CYP2D6—renal system—prostate cancer	0.00116	0.00856	CbGeAlD
L-DOPA—Methyldopa—COMT—prostate cancer	0.000889	0.0629	CrCbGaD
L-DOPA—L-Phenylalanine—TH—prostate cancer	0.00076	0.0538	CrCbGaD
L-DOPA—CYP2D6—testis—prostate cancer	0.000748	0.00553	CbGeAlD
L-DOPA—Aminosalicylic Acid—MPO—prostate cancer	0.000718	0.0508	CrCbGaD
L-DOPA—Isoetarine—ADRB2—prostate cancer	0.00065	0.046	CrCbGaD
L-DOPA—Masoprocol—CYP19A1—prostate cancer	0.00063	0.0445	CrCbGaD
L-DOPA—Mesalazine—MPO—prostate cancer	0.000563	0.0398	CrCbGaD
L-DOPA—Norepinephrine—SLC22A3—prostate cancer	0.000547	0.0386	CrCbGaD
L-DOPA—Dopamine—SLC22A3—prostate cancer	0.000508	0.0359	CrCbGaD
L-DOPA—Dopamine—COMT—prostate cancer	0.000434	0.0307	CrCbGaD
L-DOPA—SLC7A5—Desoximetasone—Prednisone—prostate cancer	0.000418	0.0438	CbGdCrCtD
L-DOPA—Norepinephrine—SLC22A1—prostate cancer	0.000392	0.0277	CrCbGaD
L-DOPA—Dopamine—SLC22A1—prostate cancer	0.000364	0.0258	CrCbGaD
L-DOPA—Epinephrine—SLC22A1—prostate cancer	0.000356	0.0251	CrCbGaD
L-DOPA—Droxidopa—ADRB2—prostate cancer	0.000297	0.021	CrCbGaD
L-DOPA—Isoprenaline—ADRB2—prostate cancer	0.00027	0.0191	CrCbGaD
L-DOPA—Aminosalicylic Acid—PTGS2—prostate cancer	0.000269	0.019	CrCbGaD
L-DOPA—Norepinephrine—ADRB2—prostate cancer	0.00025	0.0177	CrCbGaD
L-DOPA—Isoprenaline—CYP1A1—prostate cancer	0.000232	0.0164	CrCbGaD
L-DOPA—Epinephrine—ADRB2—prostate cancer	0.000227	0.016	CrCbGaD
L-DOPA—Mesalazine—PTGS2—prostate cancer	0.000211	0.0149	CrCbGaD
L-DOPA—Dopamine—CYP2C19—prostate cancer	0.0002	0.0142	CrCbGaD
L-DOPA—Vision blurred—Prednisone—prostate cancer	0.000154	0.000289	CcSEcCtD
L-DOPA—Weight decreased—Doxorubicin—prostate cancer	0.000154	0.000288	CcSEcCtD
L-DOPA—Feeling abnormal—Etoposide—prostate cancer	0.000153	0.000288	CcSEcCtD
L-DOPA—Diarrhoea—Mitoxantrone—prostate cancer	0.000153	0.000287	CcSEcCtD
L-DOPA—Dry mouth—Capecitabine—prostate cancer	0.000153	0.000287	CcSEcCtD
L-DOPA—Vomiting—Estradiol—prostate cancer	0.000153	0.000287	CcSEcCtD
L-DOPA—Agranulocytosis—Epirubicin—prostate cancer	0.000153	0.000287	CcSEcCtD
L-DOPA—Gastrointestinal pain—Etoposide—prostate cancer	0.000152	0.000286	CcSEcCtD
L-DOPA—Shock—Docetaxel—prostate cancer	0.000152	0.000286	CcSEcCtD
L-DOPA—Ill-defined disorder—Prednisone—prostate cancer	0.000152	0.000285	CcSEcCtD
L-DOPA—Thrombocytopenia—Docetaxel—prostate cancer	0.000151	0.000284	CcSEcCtD
L-DOPA—Rash—Estradiol—prostate cancer	0.000151	0.000284	CcSEcCtD
L-DOPA—Dermatitis—Estradiol—prostate cancer	0.000151	0.000284	CcSEcCtD
L-DOPA—Anaemia—Prednisone—prostate cancer	0.000151	0.000284	CcSEcCtD
L-DOPA—Confusional state—Capecitabine—prostate cancer	0.000151	0.000284	CcSEcCtD
L-DOPA—Headache—Estradiol—prostate cancer	0.00015	0.000282	CcSEcCtD
L-DOPA—Agitation—Prednisone—prostate cancer	0.00015	0.000282	CcSEcCtD
L-DOPA—Oedema—Capecitabine—prostate cancer	0.00015	0.000281	CcSEcCtD
L-DOPA—Angioedema—Prednisone—prostate cancer	0.000149	0.00028	CcSEcCtD
L-DOPA—Neuropathy peripheral—Doxorubicin—prostate cancer	0.000148	0.000279	CcSEcCtD
L-DOPA—Urticaria—Etoposide—prostate cancer	0.000148	0.000278	CcSEcCtD
L-DOPA—Haemoglobin—Epirubicin—prostate cancer	0.000148	0.000277	CcSEcCtD
L-DOPA—Anorexia—Docetaxel—prostate cancer	0.000147	0.000277	CcSEcCtD
L-DOPA—Malaise—Prednisone—prostate cancer	0.000147	0.000277	CcSEcCtD
L-DOPA—Shock—Capecitabine—prostate cancer	0.000147	0.000277	CcSEcCtD
L-DOPA—Rhinitis—Epirubicin—prostate cancer	0.000147	0.000276	CcSEcCtD
L-DOPA—Abdominal pain—Etoposide—prostate cancer	0.000147	0.000276	CcSEcCtD
L-DOPA—Urinary tract infection—Doxorubicin—prostate cancer	0.000147	0.000276	CcSEcCtD
L-DOPA—Haemorrhage—Epirubicin—prostate cancer	0.000147	0.000276	CcSEcCtD
L-DOPA—Thrombocytopenia—Capecitabine—prostate cancer	0.000147	0.000275	CcSEcCtD
L-DOPA—Syncope—Prednisone—prostate cancer	0.000147	0.000275	CcSEcCtD
L-DOPA—Hypoaesthesia—Epirubicin—prostate cancer	0.000146	0.000274	CcSEcCtD
L-DOPA—Urinary tract disorder—Epirubicin—prostate cancer	0.000145	0.000272	CcSEcCtD
L-DOPA—Hyperhidrosis—Capecitabine—prostate cancer	0.000145	0.000272	CcSEcCtD
L-DOPA—Hypotension—Docetaxel—prostate cancer	0.000144	0.000271	CcSEcCtD
L-DOPA—Urethral disorder—Epirubicin—prostate cancer	0.000144	0.00027	CcSEcCtD
L-DOPA—Loss of consciousness—Prednisone—prostate cancer	0.000144	0.00027	CcSEcCtD
L-DOPA—Anorexia—Capecitabine—prostate cancer	0.000143	0.000268	CcSEcCtD
L-DOPA—Nausea—Estradiol—prostate cancer	0.000143	0.000268	CcSEcCtD
L-DOPA—Vomiting—Mitoxantrone—prostate cancer	0.000142	0.000267	CcSEcCtD
L-DOPA—Convulsion—Prednisone—prostate cancer	0.000142	0.000266	CcSEcCtD
L-DOPA—Agranulocytosis—Doxorubicin—prostate cancer	0.000141	0.000265	CcSEcCtD
L-DOPA—Hypertension—Prednisone—prostate cancer	0.000141	0.000265	CcSEcCtD
L-DOPA—Rash—Mitoxantrone—prostate cancer	0.000141	0.000265	CcSEcCtD
L-DOPA—Dermatitis—Mitoxantrone—prostate cancer	0.000141	0.000265	CcSEcCtD
L-DOPA—Headache—Mitoxantrone—prostate cancer	0.00014	0.000263	CcSEcCtD
L-DOPA—Hypotension—Capecitabine—prostate cancer	0.00014	0.000263	CcSEcCtD
L-DOPA—Insomnia—Docetaxel—prostate cancer	0.00014	0.000263	CcSEcCtD
L-DOPA—Paraesthesia—Docetaxel—prostate cancer	0.000139	0.000261	CcSEcCtD
L-DOPA—Anxiety—Prednisone—prostate cancer	0.000139	0.00026	CcSEcCtD
L-DOPA—Dyspnoea—Docetaxel—prostate cancer	0.000138	0.000259	CcSEcCtD
L-DOPA—Somnolence—Docetaxel—prostate cancer	0.000137	0.000258	CcSEcCtD
L-DOPA—Discomfort—Prednisone—prostate cancer	0.000137	0.000258	CcSEcCtD
L-DOPA—Hypersensitivity—Etoposide—prostate cancer	0.000137	0.000257	CcSEcCtD
L-DOPA—Haemoglobin—Doxorubicin—prostate cancer	0.000136	0.000256	CcSEcCtD
L-DOPA—Flushing—Epirubicin—prostate cancer	0.000136	0.000256	CcSEcCtD
L-DOPA—Rhinitis—Doxorubicin—prostate cancer	0.000136	0.000256	CcSEcCtD
L-DOPA—Dyspepsia—Docetaxel—prostate cancer	0.000136	0.000256	CcSEcCtD
L-DOPA—Haemorrhage—Doxorubicin—prostate cancer	0.000136	0.000255	CcSEcCtD
L-DOPA—Insomnia—Capecitabine—prostate cancer	0.000135	0.000254	CcSEcCtD
L-DOPA—Hypoaesthesia—Doxorubicin—prostate cancer	0.000135	0.000254	CcSEcCtD
L-DOPA—Paraesthesia—Capecitabine—prostate cancer	0.000134	0.000253	CcSEcCtD
L-DOPA—Decreased appetite—Docetaxel—prostate cancer	0.000134	0.000252	CcSEcCtD
L-DOPA—Urinary tract disorder—Doxorubicin—prostate cancer	0.000134	0.000252	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000133	0.000251	CcSEcCtD
L-DOPA—Asthenia—Etoposide—prostate cancer	0.000133	0.000251	CcSEcCtD
L-DOPA—Dyspnoea—Capecitabine—prostate cancer	0.000133	0.000251	CcSEcCtD
L-DOPA—Oedema—Prednisone—prostate cancer	0.000133	0.00025	CcSEcCtD
L-DOPA—Fatigue—Docetaxel—prostate cancer	0.000133	0.00025	CcSEcCtD
L-DOPA—Urethral disorder—Doxorubicin—prostate cancer	0.000133	0.00025	CcSEcCtD
L-DOPA—Nausea—Mitoxantrone—prostate cancer	0.000133	0.00025	CcSEcCtD
L-DOPA—Constipation—Docetaxel—prostate cancer	0.000132	0.000248	CcSEcCtD
L-DOPA—Pain—Docetaxel—prostate cancer	0.000132	0.000248	CcSEcCtD
L-DOPA—Dyspepsia—Capecitabine—prostate cancer	0.000132	0.000248	CcSEcCtD
L-DOPA—Pruritus—Etoposide—prostate cancer	0.000132	0.000247	CcSEcCtD
L-DOPA—Shock—Prednisone—prostate cancer	0.000131	0.000246	CcSEcCtD
L-DOPA—Arrhythmia—Epirubicin—prostate cancer	0.000131	0.000246	CcSEcCtD
L-DOPA—Decreased appetite—Capecitabine—prostate cancer	0.00013	0.000244	CcSEcCtD
L-DOPA—Alopecia—Epirubicin—prostate cancer	0.00013	0.000244	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000129	0.000243	CcSEcCtD
L-DOPA—Fatigue—Capecitabine—prostate cancer	0.000129	0.000242	CcSEcCtD
L-DOPA—Hyperhidrosis—Prednisone—prostate cancer	0.000129	0.000242	CcSEcCtD
L-DOPA—Mental disorder—Epirubicin—prostate cancer	0.000129	0.000242	CcSEcCtD
L-DOPA—Constipation—Capecitabine—prostate cancer	0.000128	0.00024	CcSEcCtD
L-DOPA—Pain—Capecitabine—prostate cancer	0.000128	0.00024	CcSEcCtD
L-DOPA—Feeling abnormal—Docetaxel—prostate cancer	0.000127	0.000239	CcSEcCtD
L-DOPA—Diarrhoea—Etoposide—prostate cancer	0.000127	0.000239	CcSEcCtD
L-DOPA—Anorexia—Prednisone—prostate cancer	0.000127	0.000239	CcSEcCtD
L-DOPA—Gastrointestinal pain—Docetaxel—prostate cancer	0.000126	0.000238	CcSEcCtD
L-DOPA—Flushing—Doxorubicin—prostate cancer	0.000126	0.000237	CcSEcCtD
L-DOPA—Flatulence—Epirubicin—prostate cancer	0.000126	0.000237	CcSEcCtD
L-DOPA—Tension—Epirubicin—prostate cancer	0.000125	0.000236	CcSEcCtD
L-DOPA—Dysgeusia—Epirubicin—prostate cancer	0.000125	0.000235	CcSEcCtD
L-DOPA—Epinephrine—CYP3A4—prostate cancer	0.000124	0.00878	CrCbGaD
L-DOPA—Nervousness—Epirubicin—prostate cancer	0.000124	0.000233	CcSEcCtD
L-DOPA—Back pain—Epirubicin—prostate cancer	0.000124	0.000232	CcSEcCtD
L-DOPA—Feeling abnormal—Capecitabine—prostate cancer	0.000123	0.000232	CcSEcCtD
L-DOPA—Dizziness—Etoposide—prostate cancer	0.000123	0.000231	CcSEcCtD
L-DOPA—Muscle spasms—Epirubicin—prostate cancer	0.000123	0.000231	CcSEcCtD
L-DOPA—Gastrointestinal pain—Capecitabine—prostate cancer	0.000122	0.00023	CcSEcCtD
L-DOPA—Abdominal pain—Docetaxel—prostate cancer	0.000122	0.00023	CcSEcCtD
L-DOPA—Arrhythmia—Doxorubicin—prostate cancer	0.000121	0.000228	CcSEcCtD
L-DOPA—Insomnia—Prednisone—prostate cancer	0.000121	0.000227	CcSEcCtD
L-DOPA—Vision blurred—Epirubicin—prostate cancer	0.00012	0.000226	CcSEcCtD
L-DOPA—Alopecia—Doxorubicin—prostate cancer	0.00012	0.000225	CcSEcCtD
L-DOPA—Paraesthesia—Prednisone—prostate cancer	0.00012	0.000225	CcSEcCtD
L-DOPA—Mental disorder—Doxorubicin—prostate cancer	0.000119	0.000224	CcSEcCtD
L-DOPA—Urticaria—Capecitabine—prostate cancer	0.000119	0.000223	CcSEcCtD
L-DOPA—Ill-defined disorder—Epirubicin—prostate cancer	0.000119	0.000223	CcSEcCtD
L-DOPA—Abdominal pain—Capecitabine—prostate cancer	0.000118	0.000222	CcSEcCtD
L-DOPA—Vomiting—Etoposide—prostate cancer	0.000118	0.000222	CcSEcCtD
L-DOPA—Anaemia—Epirubicin—prostate cancer	0.000118	0.000222	CcSEcCtD
L-DOPA—Agitation—Epirubicin—prostate cancer	0.000117	0.000221	CcSEcCtD
L-DOPA—Dyspepsia—Prednisone—prostate cancer	0.000117	0.00022	CcSEcCtD
L-DOPA—Rash—Etoposide—prostate cancer	0.000117	0.00022	CcSEcCtD
L-DOPA—Dermatitis—Etoposide—prostate cancer	0.000117	0.00022	CcSEcCtD
L-DOPA—Headache—Etoposide—prostate cancer	0.000117	0.000219	CcSEcCtD
L-DOPA—Flatulence—Doxorubicin—prostate cancer	0.000116	0.000219	CcSEcCtD
L-DOPA—Tension—Doxorubicin—prostate cancer	0.000116	0.000218	CcSEcCtD
L-DOPA—Decreased appetite—Prednisone—prostate cancer	0.000116	0.000218	CcSEcCtD
L-DOPA—Dysgeusia—Doxorubicin—prostate cancer	0.000116	0.000218	CcSEcCtD
L-DOPA—Malaise—Epirubicin—prostate cancer	0.000115	0.000216	CcSEcCtD
L-DOPA—Fatigue—Prednisone—prostate cancer	0.000115	0.000216	CcSEcCtD
L-DOPA—Nervousness—Doxorubicin—prostate cancer	0.000115	0.000216	CcSEcCtD
L-DOPA—Syncope—Epirubicin—prostate cancer	0.000115	0.000215	CcSEcCtD
L-DOPA—Leukopenia—Epirubicin—prostate cancer	0.000114	0.000215	CcSEcCtD
L-DOPA—Back pain—Doxorubicin—prostate cancer	0.000114	0.000215	CcSEcCtD
L-DOPA—Constipation—Prednisone—prostate cancer	0.000114	0.000214	CcSEcCtD
L-DOPA—Hypersensitivity—Docetaxel—prostate cancer	0.000114	0.000214	CcSEcCtD
L-DOPA—Muscle spasms—Doxorubicin—prostate cancer	0.000114	0.000214	CcSEcCtD
L-DOPA—Palpitations—Epirubicin—prostate cancer	0.000113	0.000212	CcSEcCtD
L-DOPA—Loss of consciousness—Epirubicin—prostate cancer	0.000112	0.000211	CcSEcCtD
L-DOPA—Cough—Epirubicin—prostate cancer	0.000111	0.000209	CcSEcCtD
L-DOPA—Vision blurred—Doxorubicin—prostate cancer	0.000111	0.000209	CcSEcCtD
L-DOPA—Asthenia—Docetaxel—prostate cancer	0.000111	0.000208	CcSEcCtD
L-DOPA—Convulsion—Epirubicin—prostate cancer	0.000111	0.000208	CcSEcCtD
L-DOPA—Nausea—Etoposide—prostate cancer	0.00011	0.000208	CcSEcCtD
L-DOPA—Hypertension—Epirubicin—prostate cancer	0.00011	0.000207	CcSEcCtD
L-DOPA—Hypersensitivity—Capecitabine—prostate cancer	0.00011	0.000207	CcSEcCtD
L-DOPA—Feeling abnormal—Prednisone—prostate cancer	0.00011	0.000206	CcSEcCtD
L-DOPA—Ill-defined disorder—Doxorubicin—prostate cancer	0.00011	0.000206	CcSEcCtD
L-DOPA—Pruritus—Docetaxel—prostate cancer	0.000109	0.000205	CcSEcCtD
L-DOPA—Anaemia—Doxorubicin—prostate cancer	0.000109	0.000205	CcSEcCtD
L-DOPA—Gastrointestinal pain—Prednisone—prostate cancer	0.000109	0.000205	CcSEcCtD
L-DOPA—Chest pain—Epirubicin—prostate cancer	0.000109	0.000204	CcSEcCtD
L-DOPA—Agitation—Doxorubicin—prostate cancer	0.000109	0.000204	CcSEcCtD
L-DOPA—Anxiety—Epirubicin—prostate cancer	0.000108	0.000204	CcSEcCtD
L-DOPA—Discomfort—Epirubicin—prostate cancer	0.000107	0.000202	CcSEcCtD
L-DOPA—Asthenia—Capecitabine—prostate cancer	0.000107	0.000202	CcSEcCtD
L-DOPA—Malaise—Doxorubicin—prostate cancer	0.000107	0.0002	CcSEcCtD
L-DOPA—Dry mouth—Epirubicin—prostate cancer	0.000106	0.0002	CcSEcCtD
L-DOPA—Syncope—Doxorubicin—prostate cancer	0.000106	0.000199	CcSEcCtD
L-DOPA—Urticaria—Prednisone—prostate cancer	0.000106	0.000199	CcSEcCtD
L-DOPA—Pruritus—Capecitabine—prostate cancer	0.000106	0.000199	CcSEcCtD
L-DOPA—Leukopenia—Doxorubicin—prostate cancer	0.000106	0.000199	CcSEcCtD
L-DOPA—Diarrhoea—Docetaxel—prostate cancer	0.000106	0.000199	CcSEcCtD
L-DOPA—Abdominal pain—Prednisone—prostate cancer	0.000105	0.000198	CcSEcCtD
L-DOPA—Confusional state—Epirubicin—prostate cancer	0.000105	0.000198	CcSEcCtD
L-DOPA—Palpitations—Doxorubicin—prostate cancer	0.000104	0.000196	CcSEcCtD
L-DOPA—Oedema—Epirubicin—prostate cancer	0.000104	0.000196	CcSEcCtD
L-DOPA—Loss of consciousness—Doxorubicin—prostate cancer	0.000104	0.000195	CcSEcCtD
L-DOPA—Cough—Doxorubicin—prostate cancer	0.000103	0.000194	CcSEcCtD
L-DOPA—Shock—Epirubicin—prostate cancer	0.000103	0.000193	CcSEcCtD
L-DOPA—Convulsion—Doxorubicin—prostate cancer	0.000102	0.000192	CcSEcCtD
L-DOPA—Diarrhoea—Capecitabine—prostate cancer	0.000102	0.000192	CcSEcCtD
L-DOPA—Dizziness—Docetaxel—prostate cancer	0.000102	0.000192	CcSEcCtD
L-DOPA—Thrombocytopenia—Epirubicin—prostate cancer	0.000102	0.000192	CcSEcCtD
L-DOPA—Hypertension—Doxorubicin—prostate cancer	0.000102	0.000192	CcSEcCtD
L-DOPA—Hyperhidrosis—Epirubicin—prostate cancer	0.000101	0.000189	CcSEcCtD
L-DOPA—Chest pain—Doxorubicin—prostate cancer	0.000101	0.000189	CcSEcCtD
L-DOPA—Anxiety—Doxorubicin—prostate cancer	0.0001	0.000188	CcSEcCtD
L-DOPA—Discomfort—Doxorubicin—prostate cancer	9.94e-05	0.000187	CcSEcCtD
L-DOPA—Anorexia—Epirubicin—prostate cancer	9.94e-05	0.000187	CcSEcCtD
L-DOPA—Dizziness—Capecitabine—prostate cancer	9.9e-05	0.000186	CcSEcCtD
L-DOPA—Dry mouth—Doxorubicin—prostate cancer	9.84e-05	0.000185	CcSEcCtD
L-DOPA—Vomiting—Docetaxel—prostate cancer	9.83e-05	0.000185	CcSEcCtD
L-DOPA—Hypersensitivity—Prednisone—prostate cancer	9.82e-05	0.000185	CcSEcCtD
L-DOPA—Rash—Docetaxel—prostate cancer	9.75e-05	0.000183	CcSEcCtD
L-DOPA—Hypotension—Epirubicin—prostate cancer	9.74e-05	0.000183	CcSEcCtD
L-DOPA—Dermatitis—Docetaxel—prostate cancer	9.74e-05	0.000183	CcSEcCtD
L-DOPA—Confusional state—Doxorubicin—prostate cancer	9.73e-05	0.000183	CcSEcCtD
L-DOPA—Headache—Docetaxel—prostate cancer	9.69e-05	0.000182	CcSEcCtD
L-DOPA—Oedema—Doxorubicin—prostate cancer	9.65e-05	0.000181	CcSEcCtD
L-DOPA—Asthenia—Prednisone—prostate cancer	9.57e-05	0.00018	CcSEcCtD
L-DOPA—Vomiting—Capecitabine—prostate cancer	9.52e-05	0.000179	CcSEcCtD
L-DOPA—Shock—Doxorubicin—prostate cancer	9.49e-05	0.000178	CcSEcCtD
L-DOPA—Thrombocytopenia—Doxorubicin—prostate cancer	9.45e-05	0.000177	CcSEcCtD
L-DOPA—Rash—Capecitabine—prostate cancer	9.44e-05	0.000177	CcSEcCtD
L-DOPA—Pruritus—Prednisone—prostate cancer	9.43e-05	0.000177	CcSEcCtD
L-DOPA—Insomnia—Epirubicin—prostate cancer	9.43e-05	0.000177	CcSEcCtD
L-DOPA—Dermatitis—Capecitabine—prostate cancer	9.43e-05	0.000177	CcSEcCtD
L-DOPA—Headache—Capecitabine—prostate cancer	9.38e-05	0.000176	CcSEcCtD
L-DOPA—Paraesthesia—Epirubicin—prostate cancer	9.36e-05	0.000176	CcSEcCtD
L-DOPA—Hyperhidrosis—Doxorubicin—prostate cancer	9.33e-05	0.000175	CcSEcCtD
L-DOPA—Dyspnoea—Epirubicin—prostate cancer	9.3e-05	0.000175	CcSEcCtD
L-DOPA—Somnolence—Epirubicin—prostate cancer	9.27e-05	0.000174	CcSEcCtD
L-DOPA—Anorexia—Doxorubicin—prostate cancer	9.2e-05	0.000173	CcSEcCtD
L-DOPA—Nausea—Docetaxel—prostate cancer	9.18e-05	0.000173	CcSEcCtD
L-DOPA—Dyspepsia—Epirubicin—prostate cancer	9.18e-05	0.000172	CcSEcCtD
L-DOPA—Diarrhoea—Prednisone—prostate cancer	9.12e-05	0.000171	CcSEcCtD
L-DOPA—Decreased appetite—Epirubicin—prostate cancer	9.06e-05	0.00017	CcSEcCtD
L-DOPA—Hypotension—Doxorubicin—prostate cancer	9.02e-05	0.000169	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Epirubicin—prostate cancer	9e-05	0.000169	CcSEcCtD
L-DOPA—Fatigue—Epirubicin—prostate cancer	8.99e-05	0.000169	CcSEcCtD
L-DOPA—Pain—Epirubicin—prostate cancer	8.92e-05	0.000168	CcSEcCtD
L-DOPA—Constipation—Epirubicin—prostate cancer	8.92e-05	0.000168	CcSEcCtD
L-DOPA—Nausea—Capecitabine—prostate cancer	8.89e-05	0.000167	CcSEcCtD
L-DOPA—Dizziness—Prednisone—prostate cancer	8.82e-05	0.000166	CcSEcCtD
L-DOPA—Insomnia—Doxorubicin—prostate cancer	8.73e-05	0.000164	CcSEcCtD
L-DOPA—Paraesthesia—Doxorubicin—prostate cancer	8.66e-05	0.000163	CcSEcCtD
L-DOPA—Dyspnoea—Doxorubicin—prostate cancer	8.6e-05	0.000162	CcSEcCtD
L-DOPA—Feeling abnormal—Epirubicin—prostate cancer	8.59e-05	0.000161	CcSEcCtD
L-DOPA—Somnolence—Doxorubicin—prostate cancer	8.58e-05	0.000161	CcSEcCtD
L-DOPA—Gastrointestinal pain—Epirubicin—prostate cancer	8.53e-05	0.00016	CcSEcCtD
L-DOPA—Dyspepsia—Doxorubicin—prostate cancer	8.49e-05	0.00016	CcSEcCtD
L-DOPA—Vomiting—Prednisone—prostate cancer	8.48e-05	0.000159	CcSEcCtD
L-DOPA—Rash—Prednisone—prostate cancer	8.41e-05	0.000158	CcSEcCtD
L-DOPA—Dermatitis—Prednisone—prostate cancer	8.4e-05	0.000158	CcSEcCtD
L-DOPA—Decreased appetite—Doxorubicin—prostate cancer	8.39e-05	0.000158	CcSEcCtD
L-DOPA—Headache—Prednisone—prostate cancer	8.35e-05	0.000157	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Doxorubicin—prostate cancer	8.33e-05	0.000156	CcSEcCtD
L-DOPA—Fatigue—Doxorubicin—prostate cancer	8.32e-05	0.000156	CcSEcCtD
L-DOPA—Urticaria—Epirubicin—prostate cancer	8.28e-05	0.000156	CcSEcCtD
L-DOPA—Pain—Doxorubicin—prostate cancer	8.25e-05	0.000155	CcSEcCtD
L-DOPA—Constipation—Doxorubicin—prostate cancer	8.25e-05	0.000155	CcSEcCtD
L-DOPA—Abdominal pain—Epirubicin—prostate cancer	8.24e-05	0.000155	CcSEcCtD
L-DOPA—Feeling abnormal—Doxorubicin—prostate cancer	7.95e-05	0.000149	CcSEcCtD
L-DOPA—Nausea—Prednisone—prostate cancer	7.92e-05	0.000149	CcSEcCtD
L-DOPA—Gastrointestinal pain—Doxorubicin—prostate cancer	7.89e-05	0.000148	CcSEcCtD
L-DOPA—Hypersensitivity—Epirubicin—prostate cancer	7.68e-05	0.000144	CcSEcCtD
L-DOPA—Urticaria—Doxorubicin—prostate cancer	7.66e-05	0.000144	CcSEcCtD
L-DOPA—Abdominal pain—Doxorubicin—prostate cancer	7.63e-05	0.000143	CcSEcCtD
L-DOPA—Asthenia—Epirubicin—prostate cancer	7.48e-05	0.000141	CcSEcCtD
L-DOPA—Pruritus—Epirubicin—prostate cancer	7.38e-05	0.000139	CcSEcCtD
L-DOPA—Diarrhoea—Epirubicin—prostate cancer	7.13e-05	0.000134	CcSEcCtD
L-DOPA—Hypersensitivity—Doxorubicin—prostate cancer	7.11e-05	0.000134	CcSEcCtD
L-DOPA—Asthenia—Doxorubicin—prostate cancer	6.92e-05	0.00013	CcSEcCtD
L-DOPA—Dizziness—Epirubicin—prostate cancer	6.9e-05	0.00013	CcSEcCtD
L-DOPA—Pruritus—Doxorubicin—prostate cancer	6.83e-05	0.000128	CcSEcCtD
L-DOPA—Vomiting—Epirubicin—prostate cancer	6.63e-05	0.000125	CcSEcCtD
L-DOPA—Diarrhoea—Doxorubicin—prostate cancer	6.6e-05	0.000124	CcSEcCtD
L-DOPA—Rash—Epirubicin—prostate cancer	6.57e-05	0.000124	CcSEcCtD
L-DOPA—Dermatitis—Epirubicin—prostate cancer	6.57e-05	0.000123	CcSEcCtD
L-DOPA—Headache—Epirubicin—prostate cancer	6.53e-05	0.000123	CcSEcCtD
L-DOPA—Dizziness—Doxorubicin—prostate cancer	6.38e-05	0.00012	CcSEcCtD
L-DOPA—Nausea—Epirubicin—prostate cancer	6.19e-05	0.000116	CcSEcCtD
L-DOPA—Vomiting—Doxorubicin—prostate cancer	6.13e-05	0.000115	CcSEcCtD
L-DOPA—Rash—Doxorubicin—prostate cancer	6.08e-05	0.000114	CcSEcCtD
L-DOPA—Dermatitis—Doxorubicin—prostate cancer	6.08e-05	0.000114	CcSEcCtD
L-DOPA—Headache—Doxorubicin—prostate cancer	6.04e-05	0.000114	CcSEcCtD
L-DOPA—Nausea—Doxorubicin—prostate cancer	5.73e-05	0.000108	CcSEcCtD
L-DOPA—DRD5—Signaling by GPCR—IL6—prostate cancer	1.13e-05	3.85e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—INS—prostate cancer	1.13e-05	3.85e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ESR1—prostate cancer	1.12e-05	3.82e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF1R—prostate cancer	1.12e-05	3.81e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCL8—prostate cancer	1.11e-05	3.79e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—BAD—prostate cancer	1.11e-05	3.78e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCND1—prostate cancer	1.11e-05	3.78e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—JAK2—prostate cancer	1.11e-05	3.77e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CREBBP—prostate cancer	1.1e-05	3.77e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CTNNB1—prostate cancer	1.1e-05	3.74e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—BAD—prostate cancer	1.09e-05	3.73e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IGF1—prostate cancer	1.09e-05	3.72e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—EGFR—prostate cancer	1.08e-05	3.7e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NCOA2—prostate cancer	1.08e-05	3.67e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MMP9—prostate cancer	1.07e-05	3.67e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CG—prostate cancer	1.07e-05	3.66e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APC—prostate cancer	1.07e-05	3.66e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CDKN1A—prostate cancer	1.07e-05	3.65e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—LPL—prostate cancer	1.07e-05	3.65e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTEN—prostate cancer	1.07e-05	3.64e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—IL2—prostate cancer	1.06e-05	3.62e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PDGFRB—prostate cancer	1.06e-05	3.62e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGF—prostate cancer	1.06e-05	3.61e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IRS1—prostate cancer	1.06e-05	3.61e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APC—prostate cancer	1.06e-05	3.61e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CG—prostate cancer	1.06e-05	3.61e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAP2K1—prostate cancer	1.05e-05	3.59e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CB—prostate cancer	1.05e-05	3.58e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CD—prostate cancer	1.05e-05	3.57e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IRS1—prostate cancer	1.05e-05	3.57e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGF—prostate cancer	1.05e-05	3.57e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AKT1—prostate cancer	1.04e-05	3.56e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—PIK3CA—prostate cancer	1.04e-05	3.54e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SERPINE1—prostate cancer	1.04e-05	3.53e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ITGB3—prostate cancer	1.03e-05	3.53e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GSK3B—prostate cancer	1.03e-05	3.51e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC5A5—prostate cancer	1.03e-05	3.5e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—KRAS—prostate cancer	1.02e-05	3.5e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EP300—prostate cancer	1.02e-05	3.48e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GSK3B—prostate cancer	1.01e-05	3.46e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—INS—prostate cancer	1.01e-05	3.46e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL8—prostate cancer	1.01e-05	3.44e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP2E1—prostate cancer	1e-05	3.42e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FGF2—prostate cancer	1e-05	3.42e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ERBB3—prostate cancer	1e-05	3.42e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—INS—prostate cancer	1e-05	3.42e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FGFR2—prostate cancer	1e-05	3.41e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CREBBP—prostate cancer	9.94e-06	3.39e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NQO1—prostate cancer	9.92e-06	3.38e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SRC—prostate cancer	9.9e-06	3.38e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NOS3—prostate cancer	9.88e-06	3.37e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF1—prostate cancer	9.81e-06	3.35e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CREBBP—prostate cancer	9.8e-06	3.35e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TH—prostate cancer	9.78e-06	3.34e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—EGFR—prostate cancer	9.76e-06	3.33e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF1—prostate cancer	9.68e-06	3.3e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP3A4—prostate cancer	9.67e-06	3.3e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—prostate cancer	9.65e-06	3.29e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL2—prostate cancer	9.64e-06	3.29e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—EGFR—prostate cancer	9.63e-06	3.29e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—JAK2—prostate cancer	9.6e-06	3.28e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TERT—prostate cancer	9.6e-06	3.28e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—STAT3—prostate cancer	9.55e-06	3.26e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP1B1—prostate cancer	9.51e-06	3.24e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAP2K1—prostate cancer	9.48e-06	3.24e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CD—prostate cancer	9.42e-06	3.21e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PIK3CA—prostate cancer	9.41e-06	3.21e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MDM2—prostate cancer	9.38e-06	3.2e-05	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AKT1—prostate cancer	9.37e-06	3.2e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAP2K1—prostate cancer	9.36e-06	3.19e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PIK3CA—prostate cancer	9.33e-06	3.18e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SERPINE1—prostate cancer	9.32e-06	3.18e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CD—prostate cancer	9.3e-06	3.17e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ERBB2—prostate cancer	9.24e-06	3.15e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—KRAS—prostate cancer	9.22e-06	3.15e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GGT1—prostate cancer	9.21e-06	3.14e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PIK3CA—prostate cancer	9.21e-06	3.14e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SERPINE1—prostate cancer	9.19e-06	3.14e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HIF1A—prostate cancer	9.18e-06	3.13e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CB—prostate cancer	9.12e-06	3.11e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—KRAS—prostate cancer	9.1e-06	3.11e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NCOA1—prostate cancer	9.07e-06	3.1e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FGF2—prostate cancer	9.02e-06	3.08e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—LEP—prostate cancer	8.97e-06	3.06e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP19A1—prostate cancer	8.94e-06	3.05e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FGF2—prostate cancer	8.9e-06	3.04e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NOS3—prostate cancer	8.9e-06	3.04e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CAV1—prostate cancer	8.88e-06	3.03e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MYC—prostate cancer	8.88e-06	3.03e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TGFB1—prostate cancer	8.85e-06	3.02e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KDR—prostate cancer	8.78e-06	3e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NOS3—prostate cancer	8.78e-06	3e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL8—prostate cancer	8.77e-06	2.99e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EGFR—prostate cancer	8.68e-06	2.96e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—JAK2—prostate cancer	8.65e-06	2.95e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—RXRA—prostate cancer	8.63e-06	2.94e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDKN1B—prostate cancer	8.56e-06	2.92e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ESR1—prostate cancer	8.56e-06	2.92e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—JAK2—prostate cancer	8.53e-06	2.91e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3CA—prostate cancer	8.47e-06	2.89e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AKT1—prostate cancer	8.47e-06	2.89e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MDM2—prostate cancer	8.44e-06	2.88e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CASP3—prostate cancer	8.39e-06	2.86e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL2—prostate cancer	8.38e-06	2.86e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3CA—prostate cancer	8.36e-06	2.85e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—BAD—prostate cancer	8.36e-06	2.85e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL6—prostate cancer	8.34e-06	2.84e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MDM2—prostate cancer	8.33e-06	2.84e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ERBB2—prostate cancer	8.32e-06	2.84e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—COMT—prostate cancer	8.31e-06	2.84e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTP1—prostate cancer	8.27e-06	2.82e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CB—prostate cancer	8.21e-06	2.8e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ERBB2—prostate cancer	8.21e-06	2.8e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KRAS—prostate cancer	8.2e-06	2.8e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCND1—prostate cancer	8.17e-06	2.79e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ITPR1—prostate cancer	8.14e-06	2.78e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CB—prostate cancer	8.1e-06	2.76e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CG—prostate cancer	8.09e-06	2.76e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APC—prostate cancer	8.09e-06	2.76e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CTNNB1—prostate cancer	8.09e-06	2.76e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGF—prostate cancer	8e-06	2.73e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IRS1—prostate cancer	8e-06	2.73e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MMP9—prostate cancer	7.93e-06	2.71e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDKN1A—prostate cancer	7.9e-06	2.7e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL8—prostate cancer	7.89e-06	2.69e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTEN—prostate cancer	7.88e-06	2.69e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL8—prostate cancer	7.79e-06	2.66e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GSK3B—prostate cancer	7.76e-06	2.65e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDKN1B—prostate cancer	7.71e-06	2.63e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TYMS—prostate cancer	7.69e-06	2.62e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AKT1—prostate cancer	7.69e-06	2.62e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—INS—prostate cancer	7.66e-06	2.61e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AKT1—prostate cancer	7.62e-06	2.6e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDKN1B—prostate cancer	7.6e-06	2.59e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTM1—prostate cancer	7.6e-06	2.59e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CASP3—prostate cancer	7.55e-06	2.58e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL2—prostate cancer	7.54e-06	2.57e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CA—prostate cancer	7.53e-06	2.57e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AKT1—prostate cancer	7.52e-06	2.57e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EP300—prostate cancer	7.52e-06	2.57e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL6—prostate cancer	7.5e-06	2.56e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CREBBP—prostate cancer	7.5e-06	2.56e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—LPL—prostate cancer	7.46e-06	2.55e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CASP3—prostate cancer	7.45e-06	2.54e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL2—prostate cancer	7.44e-06	2.54e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF1—prostate cancer	7.41e-06	2.53e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6—prostate cancer	7.4e-06	2.53e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—EGFR—prostate cancer	7.37e-06	2.52e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCND1—prostate cancer	7.35e-06	2.51e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SRC—prostate cancer	7.31e-06	2.49e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—prostate cancer	7.29e-06	2.49e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CTNNB1—prostate cancer	7.28e-06	2.48e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCND1—prostate cancer	7.25e-06	2.48e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP1A1—prostate cancer	7.21e-06	2.46e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CTNNB1—prostate cancer	7.18e-06	2.45e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAP2K1—prostate cancer	7.16e-06	2.44e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ERCC2—prostate cancer	7.15e-06	2.44e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MMP9—prostate cancer	7.14e-06	2.44e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—prostate cancer	7.12e-06	2.43e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CD—prostate cancer	7.11e-06	2.43e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDKN1A—prostate cancer	7.11e-06	2.43e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTEN—prostate cancer	7.1e-06	2.42e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—STAT3—prostate cancer	7.05e-06	2.41e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CA—prostate cancer	7.05e-06	2.4e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP9—prostate cancer	7.04e-06	2.4e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SERPINE1—prostate cancer	7.04e-06	2.4e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDKN1A—prostate cancer	7.02e-06	2.39e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTEN—prostate cancer	7e-06	2.39e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—KRAS—prostate cancer	6.96e-06	2.38e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AKT1—prostate cancer	6.92e-06	2.36e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AKT1—prostate cancer	6.83e-06	2.33e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FGF2—prostate cancer	6.81e-06	2.32e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EP300—prostate cancer	6.77e-06	2.31e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—MTHFR—prostate cancer	6.72e-06	2.29e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOS3—prostate cancer	6.72e-06	2.29e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EP300—prostate cancer	6.68e-06	2.28e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6—prostate cancer	6.67e-06	2.28e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPARA—prostate cancer	6.59e-06	2.25e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SRC—prostate cancer	6.58e-06	2.25e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MYC—prostate cancer	6.55e-06	2.24e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TGFB1—prostate cancer	6.53e-06	2.23e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JAK2—prostate cancer	6.53e-06	2.23e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SRC—prostate cancer	6.49e-06	2.22e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—prostate cancer	6.41e-06	2.19e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EGFR—prostate cancer	6.41e-06	2.19e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CA—prostate cancer	6.4e-06	2.18e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MDM2—prostate cancer	6.37e-06	2.17e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—STAT3—prostate cancer	6.35e-06	2.17e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—prostate cancer	6.32e-06	2.16e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ERBB2—prostate cancer	6.28e-06	2.14e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—STAT3—prostate cancer	6.26e-06	2.14e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CB—prostate cancer	6.2e-06	2.12e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CAV1—prostate cancer	6.2e-06	2.11e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKT1—prostate cancer	6.16e-06	2.1e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KRAS—prostate cancer	6.05e-06	2.07e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL8—prostate cancer	5.96e-06	2.03e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MYC—prostate cancer	5.9e-06	2.01e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TGFB1—prostate cancer	5.88e-06	2.01e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MYC—prostate cancer	5.82e-06	1.99e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN1B—prostate cancer	5.82e-06	1.99e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TGFB1—prostate cancer	5.8e-06	1.98e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGFR—prostate cancer	5.77e-06	1.97e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AKT1—prostate cancer	5.76e-06	1.96e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CASP3—prostate cancer	5.7e-06	1.95e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL2—prostate cancer	5.69e-06	1.94e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGFR—prostate cancer	5.69e-06	1.94e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6—prostate cancer	5.67e-06	1.93e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CG—prostate cancer	5.64e-06	1.93e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CA—prostate cancer	5.56e-06	1.9e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCND1—prostate cancer	5.55e-06	1.89e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CTNNB1—prostate cancer	5.5e-06	1.88e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KRAS—prostate cancer	5.45e-06	1.86e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP9—prostate cancer	5.39e-06	1.84e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—prostate cancer	5.38e-06	1.84e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KRAS—prostate cancer	5.38e-06	1.83e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN1A—prostate cancer	5.37e-06	1.83e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTEN—prostate cancer	5.36e-06	1.83e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—INS—prostate cancer	5.34e-06	1.82e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CREBBP—prostate cancer	5.23e-06	1.79e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKT1—prostate cancer	5.23e-06	1.78e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EP300—prostate cancer	5.11e-06	1.74e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CA—prostate cancer	5.01e-06	1.71e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SRC—prostate cancer	4.97e-06	1.7e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CD—prostate cancer	4.96e-06	1.69e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CA—prostate cancer	4.94e-06	1.69e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6—prostate cancer	4.92e-06	1.68e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—prostate cancer	4.84e-06	1.65e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—prostate cancer	4.84e-06	1.65e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STAT3—prostate cancer	4.79e-06	1.64e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—prostate cancer	4.78e-06	1.63e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NOS3—prostate cancer	4.69e-06	1.6e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT1—prostate cancer	4.54e-06	1.55e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MYC—prostate cancer	4.45e-06	1.52e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TGFB1—prostate cancer	4.44e-06	1.52e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6—prostate cancer	4.43e-06	1.51e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6—prostate cancer	4.37e-06	1.49e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGFR—prostate cancer	4.35e-06	1.49e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CB—prostate cancer	4.33e-06	1.48e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—prostate cancer	4.29e-06	1.46e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KRAS—prostate cancer	4.11e-06	1.4e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT1—prostate cancer	4.09e-06	1.4e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT1—prostate cancer	4.04e-06	1.38e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CA—prostate cancer	3.78e-06	1.29e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTEN—prostate cancer	3.74e-06	1.28e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—prostate cancer	3.66e-06	1.25e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—EP300—prostate cancer	3.56e-06	1.22e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6—prostate cancer	3.35e-06	1.14e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT1—prostate cancer	3.09e-06	1.05e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CA—prostate cancer	2.64e-06	9e-06	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKT1—prostate cancer	2.15e-06	7.35e-06	CbGpPWpGaD
